Revolution Medicines (RVMD) announced that it has begun treating patients in RASolute 303, a global Phase 3 clinical trial evaluating daraxonrasib as monotherapy and in combination with chemotherapy in patients with previously untreated metastatic pancreatic ductal adenocarcinoma, a disease predominantly driven by oncogenic RAS variants. RASolute 303 is designed to enroll patients irrespective of tumor RAS genotype.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Revolution Medicines and Summit Therapeutics Advance Broad RAS(ON) Combo Study in Solid Tumors
- Revolution Medicines assumed with a Buy at Jefferies
- Daraxonrasib Poised to Become Pancreatic Cancer Standard of Care on Strong RASolute 302 Outlook and Accelerated Launch Path
- Erasca price target raised to $20 from $10 at Stifel
- Revolution Medicines Doubles Down on Costly RAS Push